학술논문
Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
Document Type
Article
Author
Choueiri, Toni K.; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N.; Hajek, Jaroslav; Chang, Yen-Hwa; Lee, Jae-Lyun; Sarwar, Naveed; Gurney, Howard; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B.; Sawrycki, Piotr; Zhang, Tian; Cornell, Jerry; Elfiky, Aymen; Burgents, Joseph E.; Powles, Thomas
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pLBA359-LBA359, 6p
Subject
Language
ISSN
0732183X